Sylla, Mohamed M.
Kolesinkova, Masha
da Costa, Bruna Lopes
Maumenee, Irene H.
Tsang, Stephen H.
Quinn, Peter M. J. http://orcid.org/0000-0001-9940-4264
Funding for this research was provided by:
CRBF
Article History
Received: 27 February 2023
Accepted: 25 August 2023
First Online: 7 October 2023
Declarations
:
: S.H.T receives financial support from Abeona Therapeutics, Inc and Emendo and is on the scientific and clinical advisory board for Nanoscope Therapeutics. Columbia University has filed patent applications related to <i>CRB1</i> for which B.L.D.C, S.H.T, and P.M.J.Q are listed as inventors. M.S., M.K. and I.H.M. have no conflicting interests.
: The study was conducted under the Columbia University Institutional Review Board-approved protocol IRB AAAF1849. All procedures were performed in compliance with the tenets of the Declaration of Helsinki. Informed consent was waived due to the retrospective nature of the study and the minimal risk conferred to patients as per the Columbia University Institutional Review Board-approved protocol AAAR8743.
: The study was conducted under the Columbia University Institutional Review Board-approved protocol IRB AAAF1849. All procedures were performed in compliance with the tenets of the Declaration of Helsinki.
: No animals were used in this study.
: Informed consent was waived due to the retrospective nature of the study and the minimal risk conferred to patients as per the Columbia University Institutional Review Board-approved protocol AAAR8743.